This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

EssilorLuxottica must face US antitrust claims over eyewear, plaintiffs argue

( November 20, 2024, 23:31 GMT | Official Statement) -- MLex Summary: Plaintiffs bringing US price-fixing claims against EssilorLuxottica opposed a motion to dismiss, saying their complaint plausibly alleges, in detail, the company’s staggering monopoly power and misconduct. “Through a decades-long campaign of hostile takeovers and aggressive acquisitions of competitors, EssilorLuxottica has positioned itself as the dominant force exercising market power in all aspects of the eyewear industry. […] Specifically, EssilorLuxottica has acquired an 80 percent market share of premium eyewear and a similar share in the lens market, and controls over 83 percent of US optometry practices through its vision benefits company, EyeMed,” they said.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections